fingolimod hydrochloride has been researched along with Ureteral Obstruction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, D; Tian, T; Wen, S; Zhang, J; Zhou, H; Zhu, X | 1 |
| Ferrer, FA; Hla, T; Shapiro, LH; Silva, C; Thangada, S; Yamase, H | 1 |
2 other study(ies) available for fingolimod hydrochloride and Ureteral Obstruction
| Article | Year |
|---|---|
FTY720 ameliorates renal fibrosis by simultaneously affecting leucocyte recruitment and TGF-β signalling in fibroblasts.
Topics: Animals; Cell Adhesion; Cell Line; Cell Movement; Creatinine; Extracellular Matrix; Fibroblasts; Fibrosis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney; Leukocytes; Male; Mice; Mice, Inbred C57BL; Rats; Receptors, Lysosphingolipid; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor beta; Ureteral Obstruction | 2017 |
Treatment with the immunomodulator FTY720 (fingolimod) significantly reduces renal inflammation in murine unilateral ureteral obstruction.
Topics: Animals; Blotting, Western; Disease Models, Animal; Female; Fibrosis; Fingolimod Hydrochloride; Immunohistochemistry; Immunosuppressive Agents; Inflammation; Kidney; Male; Mice; Mice, Inbred C57BL; Propylene Glycols; Sphingosine; Transforming Growth Factor beta1; Ureteral Obstruction | 2014 |